Adakras 200 mg (Adagrasib)

Adakras 200 mg (Adagrasib) bottle by Everest Pharmaceuticals Ltd., used for targeted therapy in KRAS G12C-mutated non-small cell lung cancer (NSCLC), supplied by Onco Solution.

Adakras 200 mg (Adagrasib)

Product ID: 8807

Introduction: A Revolution in Targeted Therapy

Adakras 200 mg (Adagrasib), developed by Everest Pharmaceuticals Ltd., represents a groundbreaking advancement in the treatment of KRAS G12C-mutated non-small cell lung cancer (NSCLC). As a next-generation targeted therapy, Adakras 200 mg addresses the specific needs of patients with this challenging mutation, offering hope and improved outcomes for those who have undergone prior systemic therapies. This innovative medication stands at the forefront of precision oncology, designed to inhibit the KRAS G12C mutation effectively and safely.

Mechanism of Action: Precision in Oncology

The active compound in Adakras 200 mg, Adagrasib, is a highly selective inhibitor of the KRAS G12C protein, a notorious mutation that drives cancer growth in a subset of NSCLC patients. Unlike conventional treatments that affect both cancerous and healthy cells, Adagrasib specifically targets the mutant KRAS G12C protein, irreversibly binding to it and blocking its oncogenic activity. This targeted approach not only halts tumor progression but also minimizes damage to surrounding healthy tissues, thereby reducing side effects and improving patient quality of life.

Indications and Usage: Tailored for Advanced NSCLC

Adakras 200 mg is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC harboring the KRAS G12C mutation. This medication is particularly beneficial for patients who have previously received systemic therapies but have not achieved satisfactory results. The standard recommended dose is 600 mg taken orally twice daily, with or without food. The treatment is designed to be straightforward and convenient, allowing patients to integrate it seamlessly into their daily routines while maintaining efficacy.

Clinical Efficacy: Proven Results in Extending Survival

Clinical trials have demonstrated the effectiveness of Adakras 200 mg in significantly extending progression-free and overall survival in patients with KRAS G12C-mutated NSCLC. The results indicate a substantial reduction in tumor size and a delay in disease progression, providing patients with more time and better quality of life. The success of Adagrasib in these trials underscores its potential as a cornerstone therapy for this difficult-to-treat cancer subtype.

Safety Profile: Managing Side Effects for Long-Term Use

Adakras 200 mg has been shown to have a well-tolerated safety profile, making it suitable for long-term use in patients with advanced NSCLC. Common side effects include gastrointestinal disturbances such as nausea and diarrhea, as well as fatigue. These side effects are generally manageable and can be mitigated with supportive care. Regular monitoring of blood counts and liver function is recommended to ensure ongoing treatment safety and to adjust dosing if necessary.

Dose Modifications: Personalized Treatment for Optimal Outcomes

In cases where patients experience adverse reactions, Adakras 200 mg offers flexibility in dosing. The dosage can be reduced to 400 mg or 200 mg twice daily, depending on the severity of side effects and the patient’s overall health status. This personalized approach to dosing ensures that each patient receives the optimal therapeutic benefit while minimizing potential risks.

Special Considerations: Pregnancy, Lactation, and Pediatric Use

The use of Adakras 200 mg in pregnant or lactating women is not recommended due to the potential risk to the fetus or infant. Women of childbearing potential should use effective contraception during treatment and for a specified period afterward. Additionally, the safety and efficacy of Adagrasib in pediatric populations have not been established, highlighting the need for further research in this area.

Packaging and Accessibility: Ensuring Global Reach

Each package of Adakras 200 mg contains 240 tablets, ensuring a consistent supply for patients undergoing long-term therapy. Everest Pharmaceuticals Ltd. is committed to making this life-saving treatment accessible to patients worldwide through its partnership with Onco Solution. This collaboration ensures that Adakras 200 mg reaches healthcare providers and patients across the globe, regardless of geographic barriers.

Supplier Collaboration: Onco Solution’s Role in Supplying

Onco Solution, a leader in global oncology supply, plays a crucial role in making Adakras 200 mg available to those who need it most. Through its extensive network, Onco Solution ensures that this advanced therapy is accessible to patients in diverse settings, overcoming logistical challenges and providing support throughout the treatment journey. Their expertise in oncology supply ensures that Adakras 200 mg is delivered with the care and precision required for such a critical medication.

Conclusion: Paving the Way for Future Oncology Innovations

Adakras 200 mg (Adagrasib) is not just a treatment; it is a beacon of hope for patients with KRAS G12C-mutated NSCLC. Its targeted approach, proven efficacy, and commitment to patient safety make it a transformative option in the oncology landscape. As research continues to evolve, the potential applications of Adagrasib may expand, offering new possibilities in the fight against cancer. Everest Pharmaceuticals Ltd., in partnership with Onco Solution, is dedicated to advancing cancer care, ensuring that innovative treatments like Adakras 200 mg are within reach for patients worldwide, paving the way for a brighter future in oncology.

Related Products:

Contact Us

error: Content is protected !!
Adakras 200 mg (Adagrasib) bottle by Everest Pharmaceuticals Ltd., used for targeted therapy in KRAS G12C-mutated non-small cell lung cancer (NSCLC), supplied by Onco Solution.

Request quote Now